BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming

This research was jointly conducted with Prof. Wernig at Sanford University and Prof. Rowitch at UCSF. The research was published in the online edition of ...

September 21, 2022 | News

Rapid growth puts Australian CRO Accelagen on the map for clinical research globally

Accelagen, one of Australia's leading Contract Research Organisations, has taken new 472sqM office space in Hawthorn East following two year...

September 20, 2022 | News

Redbud raises $10M in series A round as CRO focusing on science-driven clinical development

Redbud Medicine is a next-generation clinical CRO focusing on science-based clinical development services. The company offers full-service development from...

September 13, 2022 | News

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing faci...

September 12, 2022 | News

Catalent Expands Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities

The investment will increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low ...

September 07, 2022 | News

APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report

Download report here https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5In addition, the GlobalData...

September 05, 2022 | News

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility

The site's clinical manufacturing operations have an initial capacity of 4,000L and will grow to 6,000L, utilizing only single-use technology, adding to th...

September 01, 2022 | News

Porton Advanced and Royaltech Announce Strategic Collaboration to Accelerate the Development of Bacterial Drugs and mRNA Drugs

This strategic collaboration will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vec...

August 30, 2022 | News

Liminal BioSciences Announces Termination of Legacy CDMO Contract

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced today that,...

August 26, 2022 | News

Catalent to Acquire Metrics Contract Services for $475 Million

Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and sup...

August 23, 2022 | News

Selecxine, a partner of GenScript ProBio, announces FDA clearance of its IND application for innovative antibody drug program (SLC-3010)

In December 2019, GenScript ProBio announced the strategic collaboration with Selecxine for an innovative antibody drug program. The project (SLC-3010...

August 23, 2022 | News

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility

First announced in June 2021, this site will be WuXi STA's second facility in the United States, offering expanded capacity and greater flexibili...

August 17, 2022 | News

Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

Reduces process development time by an estimated 40 percent Enables biopharmaceutical companies to increase the speed to clinical manufacturing ...

August 10, 2022 | News

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

-Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vacc...

August 09, 2022 | News

Stay Connected